Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United States
/
Pharmaceuticals & Biotech
/
Pfizer
PFE
Pfizer
Pfizer's Future Depends on Oncology Growth, New Products and operational efficiency
FR
Francisco
Not Invested
Community Contributor
Published
04 Mar 25
Updated
20 Mar 25
25
Set Fair Value
1
votes
Share
Francisco
's Fair Value
US$30.62
15.5% undervalued
intrinsic discount
20 Mar
US$25.88
Loading
1Y
-10.5%
7D
3.2%
Author's Valuation
US$30.6
15.5% undervalued
intrinsic discount
Francisco's Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
Francisco
's
Fair Value
US$30.6
15.5% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-288m
93b
2014
2017
2020
2023
2025
2026
2028
Revenue US$89.0b
Earnings US$11.2b
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
-2.97%
Pharma revenue growth rate
0.58%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
6.78%
Calculation
US$11.21b
Earnings '28
x
18.55x
PE Ratio '28
=
US$208.00b
Market Cap '28
US$208.00b
Market Cap '28
/
5.67b
No. shares '28
=
US$36.69
Share Price '28
US$36.69
Share Price '28
Discounted to 2025 @ 6.21% p.a.
=
US$30.62
Fair Value '25
